10:59 AM
 | 
Aug 23, 2018
 |  BC Innovations  |  Translation in Brief

LRRK2 looming larger

University of Pittsburgh team links LRRK2 activity to idiopathic PD

Researchers from the University of Pittsburgh have identified a link between LRRK2 activity and idiopathic forms of Parkinson’s disease, further broadening the potential patient population for LRRK2 inhibitors in development, including two clinical compounds from Denali Therapeutics Inc. (NASDAQ: DNLI).

Multiple gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) have been implicated in autosomal dominant forms of Parkinson’s disease. However, the role of LRRK2 in the larger idiopathic PD patient population has been unclear.

“Both internal and external evidence are really starting to point to LRRK2 being activated in non-mutation carriers.”

Ryan Watts, Denali

In a July paper published in Science Translational Medicine, a University of Pittsburgh team developed a method to detect LRRK2 activity and found that increased...

Read the full 577 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >